Abstract | PURPOSE: To assess the value of scintigraphy with [123I]N-(2-diethylaminoethyl)-4-iodobenzamide (BZA), a phase II clinical trial was performed on 48 patients with a suspicion of ocular melanoma. METHODS: 56 examinations were performed to image lesions with a clinical diagnosis of primary ocular melanoma before and/or after treatment, to observe the results in simulating lesions or to image metastases. RESULTS: Ocular BZA-scintigraphy demonstrated a sensitivity of 86%, and a specificity of 83%. Whole-body scintigraphy was used in the follow-up of treated patients and could be repeated. We imaged orbital recurrence, known and occult metastases, specially in the liver. After 9 conservative treatments ocular BZA-scintigraphy was negative in 9 eyes. CONCLUSION: The BZA-scintigraphy in combination with other diagnostic procedures appeared to be a suitable method in the diagnosis of ocular melanoma and a potentially useful imaging modality to screen for ocular malignant melanoma metastases.
|
Authors | F Bacin, J Michelot, J Bonafous, A Veyre, M F Moreau, J L Kemeny, F Chossat, D Bekhechi |
Journal | Acta ophthalmologica Scandinavica
(Acta Ophthalmol Scand)
Vol. 76
Issue 1
Pg. 56-61
(Feb 1998)
ISSN: 1395-3907 [Print] Denmark |
PMID | 9541435
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Benzamides
- Contrast Media
- N-(2-(diethylamino)ethyl)-4-iodobenzamide
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Benzamides
- Brachytherapy
- Conjunctival Neoplasms
(diagnostic imaging, pathology, therapy)
- Contrast Media
- Eye Enucleation
- Female
- Humans
- Laser Coagulation
- Liver Neoplasms
(diagnostic imaging, secondary, therapy)
- Lung Neoplasms
(diagnostic imaging, secondary, therapy)
- Male
- Melanoma
(diagnostic imaging, secondary, therapy)
- Middle Aged
- Radionuclide Imaging
- Sensitivity and Specificity
- Uveal Neoplasms
(diagnostic imaging, pathology, therapy)
|